Sermorelin

Overview

Sermorelin is a synthetic peptide corresponding to the N-terminal 29 amino acids of growth hormone–releasing hormone (GHRH). GHRH is the hypothalamic peptide that signals to the anterior pituitary to release growth hormone in physiological pulses, predominantly during slow-wave sleep. The 1-29 fragment retains essentially the full biological activity of the 44-amino-acid native peptide and was developed as a clinical-grade GHRH analogue.

Sermorelin was approved by the US FDA in 1997 under the brand name Geref for diagnostic use in paediatric GH-deficiency assessment and was subsequently used as an off-label adjunct in adult GH-axis restoration before the manufacturer voluntarily withdrew the product from US distribution in 2008 for commercial reasons rather than safety concerns.

Sermorelin's relevance to longevity research stems from a single observation: pituitary GH output declines progressively across the adult lifespan — the 'somatopause' — driven primarily by reduced hypothalamic GHRH output rather than by pituitary failure. Stimulating residual pituitary capacity with a GHRH analogue produces pulsatile, feedback-regulated GH/IGF-1 elevation that resembles youthful physiology more closely than exogenous recombinant GH supplementation.

This page summarises the published mechanism, clinical history, longevity-relevant research and UK regulatory framing.

Mechanism of action

Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, activating Gs-coupled adenylate cyclase signalling and triggering pulsatile release of growth hormone from intracellular stores. The mechanism is identical to that of endogenous hypothalamic GHRH and is the upstream physiological signal for GH secretion.

Critically, sermorelin-induced GH release is subject to normal negative feedback. Circulating IGF-1, elevated GH itself, and hypothalamic somatostatin all act to limit the pituitary response — meaning that supraphysiological GH levels are difficult to produce with GHRH analogues, in contrast with administration of recombinant human GH. This feedback-preserved pharmacology is the principal rationale for using GHRH analogues in age-related GH decline research.

GH released in response to sermorelin produces the standard downstream cascade: hepatic IGF-1 production, modest lipolytic effects on adipose tissue, and anabolic effects on protein synthesis in skeletal muscle and connective tissue. Because release is pulsatile and feedback-regulated, the IGF-1 elevation profile resembles natural diurnal patterns rather than the sustained elevation seen with recombinant GH supplementation.

The somatopause — the age-related decline in GH output — is mediated primarily by reduced hypothalamic GHRH output and increased somatostatin tone, with pituitary capacity largely preserved. This makes pituitary stimulation by a GHRH analogue a reasonable physiological intervention to test in age-related GH decline, although the long-term consequences of restoring younger GH/IGF-1 profiles in older adults remain an active research question with conflicting longevity-biology arguments.

Research history

Sermorelin was developed in the 1980s as a clinical-grade GHRH analogue. FDA approval came in 1997 under the brand name Geref, principally for paediatric GH-deficiency diagnosis and adjunct treatment. Adult off-label use developed through the 2000s in age-related GH decline contexts, and the product was voluntarily withdrawn from US commercial distribution in 2008.

Subsequent compounded preparations have continued to be available through specialist compounding pharmacies in some US jurisdictions, predominantly for adult age-management indications. Research-grade material is available internationally for laboratory and preclinical work.

Within the longevity research literature, sermorelin and related GHRH analogues (CJC-1295 — covered separately on this site) have been studied for effects on body composition, sleep architecture, IGF-1 levels and well-being scores in older adults. Outcomes are generally consistent with modest, feedback-regulated GH/IGF-1 elevation; long-term healthspan and lifespan implications remain unresolved.

Summarised studies